| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-02-17 | ozanimod - RPC1063 | multiple sclerosis | 3 | Celgene (USA - NJ) | Autoimmune diseases - Neurodegenerative diseases |
| 2017-02-17 | BPM 31510-IV (ubidecarenone) | gliosarcoma, recurrent glioblastoma | 1-2 | National Cancer Institute (NCI) BERG (USA - MA) | Cancer - Oncology |
| 2017-02-17 | cabozantinib in combination with either nivolumab or nivolumab plus ipilimumab | refractory genitourinary tumors | 1 | Exelixis (USA - CA) | Cancer - Oncology |
| 2017-02-17 | cabozantinib, nivolumab and ipilimumab | urothelial cancer, bladder cancer, genitourinary cancer, urogenital neoplasms, urogenital cancer | 1 | National Cancer Institute (NCI) (USA) | Cancer - Oncology |
| 2017-02-16 | selonsertib (GS-4997) | NASH (non-alcoholic steatohepatitis) | 3 | Gilead Sciences (USA - CA) | Hepatic diseases - Liver diseases |
| 2017-02-16 | GBT440 | 1 | Global Blood Therapeutics (USA - CA) | Hematological diseases | |
| 2017-02-16 | AGT-181 (fusion protein of anti-human insulin receptor monoclonal antibody and alpha-L-iduronidase; HIRMAb-IDUA) | mucopolysaccharidosis I (Hurler syndrome) | 1-2 | Armagen (USA - CA) | Rare diseases - Genetic diseases |
| 2017-02-16 | TRC105 | advanced angiosarcoma | 3 | Tracon Pharmaceuticals (USA - CA) | Cancer - Oncology |
| 2017-02-16 | WTX101 (bis-choline tetrathiomolybdate) | Wilson disease | 3 | Wilson Therapeutics (Sweden) | Rare diseases - Metabolic diseases |
| 2017-02-16 | TransCon Growth Hormone | growth hormone deficiency | 2 | Ascendis Pharma (Denmark) | Endocrine diseases - Hormonal diseases |
| 2017-02-15 | baricitinib (LY3009104) | rheumatoid arthritis | 3 | Eli Lilly (USA - IN) Incyte Corporation (USA - DE) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2017-02-15 | tenapanor | hyperphosphatemia in end-stage renal disease patients on hemodialysis | 3 | Ardelyx (USA - CA) | |
| 2017-02-14 | GZ/SAR402671 | Parkinson's disease | 2 | Genzyme (USA - MA), a Sanofi company (France) | Neurodegenerative diseases |
| 2017-02-14 | GBT440 | preclinical | Global Blood Therapeutics (USA - CA) | ||
| 2017-02-14 | verubecestat (MK-8931) | Alzheimer's Disease | 2-3 | Merck&Co (USA - NJ) | Neurodegenerative diseases |
| 2017-02-14 | Acarovac MPL (monophosphoryl lipid A) | house dust mite allergy | 1 | Allergy Therapeutics (UK) | Allergic diseases |
| 2017-02-14 | Genvoya® (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg or E/C/F/TAF) | HIV-1 infection | 3 | Gilead (USA - CA) | Infectious diseases |
| 2017-02-13 | navicixizumab - anti-DLL4/VEGF bispecific antibody (OMP-305B83) | ovarian cancer | 1b-2 | OncoMed Pharmaceuticals (USA - CA) | Cancer - Oncology |
| 2017-02-13 | BAY1834845 | pelvic inflammatory disease | 1 | Bayer (Germany) | Inflammatory diseases |
| 2017-02-13 | Pexa-Vec (pexastimogene devacirepvec) | metastatic and/or locally advanced solid tumors | 1 | Transgene (France) Centre Leon Berard (France) | Cancer - Oncology |
